{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-043424","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2022-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.894564+00:00","generated_at":"2026-06-26T08:51:54.999598+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Black Diamond Therapeutics appoints Wendy L. Dixon to board; Brad Bolzon resigns","bullets":["Brad Bolzon resigned from the Board effective April 5, 2022; not due to any disagreement with the company.","Wendy L. Dixon, Ph.D., appointed as Class III director effective April 6, 2022; deemed independent under Nasdaq rules.","Dr. Dixon brings over 40 years biopharma experience, including former CMO of Bristol Myers Squibb and board seats at Alkermes, Incyte, Arvinas.","She will receive standard non-employee director compensation and enter into an indemnification agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-043424","json":"https://secwatch.observer/filing/0001104659-22-043424.json","markdown":"https://secwatch.observer/filing/0001104659-22-043424.md","text":"https://secwatch.observer/filing/0001104659-22-043424.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000110465922043424/0001104659-22-043424-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000110465922043424/tm2211759d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T08:51:54.999598+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"28b991fc80","claim":"Brad Bolzon resigned as Director at Black Diamond Therapeutics, Inc..","evidence_excerpt":"On April 5, 2022, Brad Bolzon, Ph.D. notified Black Diamond Therapeutics, Inc. (the “Company”) of his intent to resign from the Company’s Board of Directors (the “Board”), effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465922043424/0001104659-22-043424-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6af78ab140","claim":"Wendy L. Dixon was appointed as Class III Director at Black Diamond Therapeutics, Inc..","evidence_excerpt":"On April 6, 2022 (the “Effective Date”), upon the recommendation of its Compensation, Nomination and Corporate Governance Committee, the Board appointed Wendy L. Dixon, Ph.D. to serve on the Board as a Class III director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465922043424/0001104659-22-043424-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}